BioMed Research International

Research Article

Rational Application of First-Line EGFR-TKIs Combined with Antiangiogenic Inhibitors in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Table 1

The characteristics of the included studies.


Study/author name	JO25567 [12]		Kitagawa C [19]		Stinchcombe T [20]		NEJ026 [13]		RELAY [15]		CTONG1509 [14]

Study phase	Phase II RCT		Phase II RCT		Phase II RCT		Phase III RCT		Phase III RCT		Phase III RCT
Study arms		Erl		Gef		Erl		Erl		Erl		Erl
No. of patients ()	75	77	6	10	43	45	112	112	224	225	157	154
Median age, years	67	67	73.5	72.5	65	63	67	68	65	64	NR	NR
Male (, %)	30 (40%)	26 (33.8%)	1 (16.7%)	3 (30%)	12 (27.9%)	14 (31.1%)	41 (36.6%)	39 (34.8%)	83 (37.1%)	83 (36.9%)	60 (38.2%)	58 (37.7%)
Never smoker	42 (56%)	45 (58.4%)	4 (66.7%)	8 (80%)	25 (58.1%)	23 (51.1%)	65 (58%)	64 (54.5%)	134 (59.8%)	139 (61.8%)	NR	NR
Former smoker	9 (12%)	6 (7.8%)	2 (33.3%)	2 (20%)	14 (32.6%)	15 (33.3%)	6 (5.4%)	7 (6.3%)	NR	NR	NR	NR
EGFR L858R (, %)	35 (46.7%)	37 (48.1%)	2 (33.3%)	3 (30%)	14 (32.6%)	15 (33.3%)	56 (50%)	57 (50.9%)	99 (44.2%)	105 (46.7%)	75 (47.8%)	75 (48.7%)
ECOG PS 1 (, %)	32 (42.7%)	36 (46.8%)	4 (66.7%)	3 (30%)	19 (44.2%)	26 (57.8%)	48 (42.9%)	42 (37.5%)	108 (48.2%)	106 (47.1%)	132 (84.1%)	137 (89%)
Adenocarcinoma (, %)	74 (98.7%)	76 (98.7%)	6 (100%)	9 (90%)	NR	NR	110 (98.2%)	112 (100%)	215 (96%)	218 (96.9%)	157 (100%)	154 (100%)
Stage IIIB (, %)	1 (1%)	0	0	1 (10%)	NR	NR	8 (7.1%)	8 (7.1%)	NR	NR	4 (2.6%)	6 (3.9%)
Stage IV (, %)	60 (80%)	62 (80.5%)	6 (100%)	9 (90%)	39 (90.7%)	39 (86.7%)	82 (73.2%)	84 (75%)	195 (87.1%)	189 (84%)	141 (89.8%)	134 (87%)
Recurrence (, %)	14 (18.6%)	15 (19.5%)	NR	NR	NR	NR	22 (19.6%)	20 (19.6%)	NR	NR	12 (7.6%)	14 (9.1%)
Brain metastases (, %)	NR	NR	NR	NR	11 (25.6%)	14 (31.1%)	36 (32.1%)	36 (32.1%)	NR	NR	44 (28%)	47 (30.5%)
Treatment duration, median (days)	Bev:326 Erl:431	254	NR		NR		Bev: 350 Erl: 405	364	Bev: 308 Erl: 395	314	Bev: 462 Erl: 551	377

Bev: bevacizumab; Erl: erlotinib; Ram: ramucirumab; 19del: EGFR exon 19 deletion; L858R: EGFR L858R mutation; ECOG PS: Eastern Cooperative Oncology Group performance status scores; NR: not reported.